These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 28152356)
1. Cardiovascular disease in patients with schizophrenia. Kritharides L; Chow V; Lambert TJ Med J Aust; 2017 Feb; 206(2):91-95. PubMed ID: 28152356 [TBL] [Abstract][Full Text] [Related]
2. Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014. Hollingworth SA; Winckel K; Saiepour N; Wheeler AJ; Myles N; Siskind D Psychopharmacology (Berl); 2018 Jul; 235(7):1915-1921. PubMed ID: 29589067 [TBL] [Abstract][Full Text] [Related]
3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness]. Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM; Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369 [TBL] [Abstract][Full Text] [Related]
4. Metabolic monitoring and management among clozapine users. Tso G; Kumar P; Jayasooriya T; Kisely S; Siskind D Australas Psychiatry; 2017 Feb; 25(1):48-52. PubMed ID: 27590080 [TBL] [Abstract][Full Text] [Related]
5. Clozapine-induced cardiomyopathy and myocarditis monitoring: A systematic review. Knoph KN; Morgan RJ; Palmer BA; Schak KM; Owen AC; Leloux MR; Patel M; Leung JG Schizophr Res; 2018 Sep; 199():17-30. PubMed ID: 29548760 [TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Youssef DL; Narayanan P; Gill N Australas Psychiatry; 2016 Apr; 24(2):176-80. PubMed ID: 26400457 [TBL] [Abstract][Full Text] [Related]
8. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study. Taub S; Hoshen M; Balicer R; Kamhi-Nesher S; Weizman A; Krivoy A Eur Neuropsychopharmacol; 2020 Dec; 41():63-69. PubMed ID: 32981820 [TBL] [Abstract][Full Text] [Related]
9. Development of a health screening clinic. Millar HL Eur Psychiatry; 2010 Jun; 25 Suppl 2():S29-33. PubMed ID: 20620883 [TBL] [Abstract][Full Text] [Related]
10. Myocarditis and cardiomyopathy associated with clozapine. Kilian JG; Kerr K; Lawrence C; Celermajer DS Lancet; 1999 Nov; 354(9193):1841-5. PubMed ID: 10584719 [TBL] [Abstract][Full Text] [Related]
11. Update on the adverse effects of clozapine: focus on myocarditis. De Berardis D; Serroni N; Campanella D; Olivieri L; Ferri F; Carano A; Cavuto M; Martinotti G; Cicconetti A; Piersanti M; Saverio Moschetta F; Di Giannantonio M Curr Drug Saf; 2012 Feb; 7(1):55-62. PubMed ID: 22663959 [TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia. Quek YF; See YM; Yee JY; Rekhi G; Ng BT; Tang C; Lee J Asian J Psychiatr; 2022 Aug; 74():103192. PubMed ID: 35751958 [TBL] [Abstract][Full Text] [Related]
14. Myocarditis after administration of clozapine. Kontoangelos K; Loizos S; Kanakakis J; Smyrnis N; Economou M; Bergiannaki JD; Papadimitriou GN Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2383-6. PubMed ID: 25219841 [TBL] [Abstract][Full Text] [Related]
15. Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine. Wehmeier PM; Schüler-Springorum M; Heiser P; Remschmidt H J Child Adolesc Psychopharmacol; 2004; 14(2):267-71. PubMed ID: 15319023 [TBL] [Abstract][Full Text] [Related]
16. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia. Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178 [TBL] [Abstract][Full Text] [Related]
17. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Reinders J; Parsonage W; Lange D; Potter JM; Plever S Aust N Z J Psychiatry; 2004; 38(11-12):915-22. PubMed ID: 15555025 [TBL] [Abstract][Full Text] [Related]
18. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial. Storch Jakobsen A; Speyer H; Nørgaard HCB; Hjorthøj C; Krogh J; Mors O; Nordentoft M Schizophr Res; 2018 Sep; 199():96-102. PubMed ID: 29501386 [TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Siskind D; Sidhu A; Cross J; Chua YT; Myles N; Cohen D; Kisely S Aust N Z J Psychiatry; 2020 May; 54(5):467-481. PubMed ID: 31957459 [TBL] [Abstract][Full Text] [Related]
20. Rapid Rechallenge with Clozapine Following Pronounced Myocarditis in a Treatment-Resistant Schizophrenia Patient. Ittasakul P; Archer A; Kezman J; Atsariyasing W; Goldman MB Clin Schizophr Relat Psychoses; 2016; 10(2):120-2. PubMed ID: 27440213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]